Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Schedule of Revenue Associated with License Agreement

We recognized revenue associated with the KKC Commercialization Agreement for the periods presented (in thousands):

	For the Fiscal Year Ended June 30,
	2024		2023
Timing of Revenue Recognition:
Services performed over time	$	743	$	47,729
Pass through services at a point in time		9		1,087
	$	752	$	48,816

Schedule of Changes in Accounts Receivable, Unbilled Receivables and Contract Liabilities

As of June 30, 2024 and 2023, we had no balances in accounts receivable. Contract balances are as follows (in thousands):

	June 30, 2024		June 30, 2023		June 30, 2022
Unbilled receivables	$	—	$	85	$	10,044
Contract liabilities included in deferred revenue and     deferred revenue, net of current portion	$	—	$	317	$	30,900

A reconciliation of the beginning and ending amount of contract liabilities, which are primarily related to the combined performance obligation for the transfer of development services under the KKC Commercialization Agreement and are a separate performance obligation in our contracts pursuant to research plans under the agreements, was as follows for the periods presented:

	June 30, 2024			June 30, 2023
Beginning balance	$	317		$	30,900
Recognized as revenue:
Revenue recognized upon satisfaction of performance obligations		(317	)		(5,411	)
Revenue recognized from change in estimate for performance     obligations that are being closed		—			(16,565	)
Revenue recognized for performance obligations that will no longer     commence		—			(8,607	)
Ending balance	$	—		$	317

Antidilutive Securities

The following table presents potentially dilutive shares that have been excluded from the calculation of net income (loss) per share because of their anti-dilutive effect (in thousands):

	For the Fiscal Year Ended June 30,
	2024		2023
Stock options		1,357		1,285
Warrants		103		103
Total anti-dilutive shares		1,460		1,388